India Pharma Outlook Team | Saturday, 12 July 2025
India’s pharmaceutical sector is focused on a major goal of increasing exports to USD 1 trillion, and biosimilars are emerging as the cornerstone of this growth. Currently valued at USD 50–55 billion, pharmaceutical exports from India are expected to grow at a CAGR of 11–12%, more than double the global average for generics.
A recent report from an industry group points out that biosimilars alone could create opportunites worth around USD 60 billion as demand pressures emerge in markets such as the US and Europe.
Indian companies like Biocon, Dr. Reddy's, and Cipla are already market participants and developing their global biologics credentials, spending on R&D, manufacturing, and regulatory training in order to tap this high-value segment. In order to realise this target, the sector needs to come together and unite for a common cause.
Also Read: Cost-Effectiveness of Minimally Invasive Surgery in Outpatient Settings
Industry leaders have been working with the government, regulators, and embassies to concentrate efforts into productive synergies. The CDSCO and Commerce ministry will play a key role in establishing the biosimilar regulations, as well as in international outreach.
Despite a dip in export growth in April–May, momentum remains strong following a robust March. With global healthcare systems eyeing cost-effective biologic alternatives, India’s biosimilar strength could redefine its pharma leadership in the coming years.
